These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 13773272)

  • 1. Active immunization of mice against Candida albicans.
    MOURAD S; FRIEDMAN L
    Proc Soc Exp Biol Med; 1961 Mar; 106():570-2. PubMed ID: 13773272
    [No Abstract]   [Full Text] [Related]  

  • 2. Experimental vaccination with Candida albicans ribosomes in cyclophosphamide-treated animals.
    Segal E; Sandovsky-Losica H
    Sabouraudia; 1981 Dec; 19(4):267-73. PubMed ID: 7034238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection against systemic infections with various Candida species elicited by vaccination with Candida albicans ribosomes.
    Segal E; Nussbaum S; Barr-Nea L
    Sabouraudia; 1985 Aug; 23(4):275-85. PubMed ID: 3901330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Value of cutaneous tests in allergy to Candida albicans].
    SCLAFER J; HEWITT J
    Pathol Biol; 1960 Feb; 8():323-7. PubMed ID: 14444172
    [No Abstract]   [Full Text] [Related]  

  • 5. [Electrophoretic, chromatographic and immunological study of blod proteins of rabbits immunized against Candida albicans].
    BIGUET J; TRAN-VAN-KY P; HAVEZ R; ANDRIEU S
    Ann Inst Pasteur (Paris); 1962 Mar; 102():328-38. PubMed ID: 13869148
    [No Abstract]   [Full Text] [Related]  

  • 6. Testing Antifungal Vaccines in an Animal Model of Invasive Candidiasis and in Human Mucosal Candidiasis.
    Segal E
    Methods Mol Biol; 2017; 1625():343-353. PubMed ID: 28585001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Serology and cutaneous allergy to Candida albicans. Comparative study].
    RIMBAUD P; RIOUX JA; DUNTZE F; BASTIDE JM
    Montp Med; 1961 Jan; 59():59-65. PubMed ID: 13741705
    [No Abstract]   [Full Text] [Related]  

  • 8. Increased resistance in BALB/c mice to reinfection with Candida albicans is due to immunoneutralization of a virulence-associated immunomodulatory protein.
    Tavares D; Ferreira P; Arala-Chaves M
    Microbiology (Reading); 2003 Feb; 149(Pt 2):333-339. PubMed ID: 12624195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active immunisation of mice against muscle damage mediated by Candida albicans.
    Oblack DL; Holder IA
    J Med Microbiol; 1979 Nov; 12(4):503-6. PubMed ID: 390156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Attempted vaccination against Candida in experimental animals].
    CASOTTI O; FRASCARELLI F
    Nuovi Ann Ig Microbiol; 1959; 10():402-9. PubMed ID: 13808172
    [No Abstract]   [Full Text] [Related]  

  • 11. [Immunoprotection by Sap2 and dendritic cells against systemic Candida albicans infection in mice].
    Xu M; Liu J
    Nan Fang Yi Ke Da Xue Xue Bao; 2014 Jun; 34(7):1030-4. PubMed ID: 25057078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological and pathological observations with Candida albicans-infected animals.
    Kuttin ES; Müller J; Douchet C; Vogt A
    Sabouraudia; 1983 Sep; 21(3):185-94. PubMed ID: 6356407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity.
    Ibrahim AS; Spellberg BJ; Avenissian V; Fu Y; Filler SG; Edwards JE
    Infect Immun; 2005 Feb; 73(2):999-1005. PubMed ID: 15664943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental investigation of immunreactivity against Candida albicans. 2. The effect of azathioprin (Imuran) on immunreactivity against Candida albicans.
    Kakuk G; Balogh E; Szabolcsi M; Halmy K
    Mykosen; 1972 Feb; 15(2):73-82. PubMed ID: 4553263
    [No Abstract]   [Full Text] [Related]  

  • 15. Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis.
    Han Y; Ulrich MA; Cutler JE
    J Infect Dis; 1999 Jun; 179(6):1477-84. PubMed ID: 10228070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Post-Vaccination Phagocytic Activation Using Candida albicans Killing Assays.
    Li W; Hu Y
    Methods Mol Biol; 2017; 1625():313-326. PubMed ID: 28584999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response of mice to inoculations of both Candida albicans and Escherichia coli. II. The effect of the strain of mice.
    GALE D; DEVESTY G
    J Infect Dis; 1957; 101(1):48-50. PubMed ID: 13463382
    [No Abstract]   [Full Text] [Related]  

  • 18. Protection of mice from lethal endogenous Candida albicans infection by immunization with Candida membrane antigen.
    Tansho S; Ab S; Mizutani S; Ono Y; Takesako K; Yamaguchi H
    Microbiol Immunol; 2002; 46(5):307-11. PubMed ID: 12139389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A proteomic-based approach for the identification of Candida albicans protein components present in a subunit vaccine that protects against disseminated candidiasis.
    Thomas DP; Viudes A; Monteagudo C; Lazzell AL; Saville SP; López-Ribot JL
    Proteomics; 2006 Nov; 6(22):6033-41. PubMed ID: 17051645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of mice to the inoculations of both Candida albicans and Escherichia coli. I. The enhancement phenomenon.
    GALE D; SANDOVAL B
    J Bacteriol; 1957 May; 73(5):616-24. PubMed ID: 13428706
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.